Nathalie Bendriss-Vermare

13PUBLICATIONS
45CO-AUTHORS
Innate immunityGene and molecular therapyPredictive and prognostic markersMolecular targetsCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Nov 14, 2025
Dendritic cells: the central partner for cancer immunity.

Léo Laoubi, Elisa Gobbini, Pierre Duplouye

|Jul 03, 2025
Interleukin-35 impairs human NK cell effector functions and induces their ILC1-like conversion with tissue residency features.

Valentin Picant, Lara Revol-Bauz, Laurie Tonon

|Mar 29, 2025
Type III interferon primes pDCs for TLR7 activation and antagonizes immune suppression mediated by TGF-β and PGE2.

Candice Sakref, Alexis Saby, Céline Rodriguez

|Jan 24, 2024
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.

Aurélien Voissière, Carlos Gomez-Roca, Sylvie Chabaud

|May 06, 2022
Diversification of circulating and tumor-infiltrating plasmacytoid DCs towards the P3 (CD80+ PDL1-)-pDC subset negatively correlated with clinical outcomes in melanoma patients.

Eleonora Sosa Cuevas, Nathalie Bendriss-Vermare, Stephane Mouret

|Mar 15, 2022
Combinatorial Expression of NK Cell Receptors Governs Cell Subset Reactivity and Effector Functions but Not Tumor Specificity.

Yamila Rocca, Kevin Pouxvielh, Marie Marotel

Pageof 3

Frequent Collaborators

4 joint publications

Aurélien Voissière

3 joint publications

Eleonora Sosa Cuevas

3 joint publications

Margaux Hubert

3 joint publications

Caroline Aspord